Understanding Vardenafil 5 mg for Erectile Dysfunction

vardenafil increases effects of prazosin by pharmacodynamic synergism. ribociclibribociclib increases toxicity of vardenafil by QTc interval. ribociclib increases toxicity of vardenafil by QTc interval. rifabutinrifabutin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifabutin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifampinrifampin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifampin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. sevofluranesevoflurane and vardenafil both increase QTc interval.

Concept Hierarchy & Relationship Mapping

itraconazoleitraconazole and vardenafil both increase QTc interval. itraconazole and vardenafil both increase QTc interval. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternative therapies. If ed tablets coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs.

Medications & Supplements

If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation. macimorelinmacimorelin and vardenafil both increase QTc interval. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin. sevoflurane and vardenafil both increase QTc interval.

silodosinvardenafil increases effects of silodosin by pharmacodynamic synergism. vardenafil increases effects of silodosin by pharmacodynamic synergism. siponimod and vardenafil both increase QTc interval. St John's WortSt John's Wort will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

St John's Wort will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. terazosinvardenafil increases effects of terazosin by pharmacodynamic synergism. vardenafil increases effects of terazosin by pharmacodynamic synergism. tetrabenazinetetrabenazine and vardenafil both increase QTc interval. tetrabenazine and vardenafil both increase QTc interval. tovorafenibtovorafenib will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Vardenafil 5 mg is available in tablet form for oral use.
• It is important to complete the full course unless advised otherwise.
• The medication’s effect can be delayed or reduced by certain foods.
• Regular medical follow-up enhances safe use.
• Patients should inform the doctor of all medications they are taking.
• Its efficacy can be reduced by smoking or excessive alcohol.
• Use with caution in elderly patients due to increased sensitivity.
• Label instructions should be carefully read before use.
• Over-the-counter use without consultation is discouraged.
• Vardenafil 5 mg does not protect against pregnancy or STDs.
• Maintain a healthy weight to improve medication effectiveness.
• Report any allergic reactions like rash or swelling immediately.

Avoid coadministration of tovorafenib (a weak CYP3A4 inducer) with CYP3A substrates where minimal lovegra women concentration changes may lead to serious therapeutic failures. If unavoidable, monitor patients for loss of efficacy unless otherwise recommended in the CYP3A4 substrate prescribing information. tovorafenib will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Before taking this medicine

carbamazepine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ceritinib and vardenafil both increase QTc interval. clarithromycinclarithromycin and vardenafil both increase QTc interval. clarithromycin and vardenafil both increase QTc interval. danazoldanazol will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Visual disturbances

danazol will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. doxazosinvardenafil increases effects of doxazosin by pharmacodynamic synergism. vardenafil increases effects of doxazosin by pharmacodynamic synergism. entrectinib and vardenafil both increase QTc interval. eribulin and vardenafil both increase QTc interval. tucatinibtucatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling.

• Vardenafil 5 mg is used to treat erectile dysfunction in men.
• It works by increasing blood flow to the penis.
• Vardenafil 5 mg usually starts working within 30-60 minutes.
• The typical dosage for Vardenafil 5 mg is once daily.
• It is available by prescription only.
• Vardenafil 5 mg may cause side effects like headache or flushing.
• It is more effective when taken on an empty stomach.
• Alcohol can increase the risk of side effects with Vardenafil.
• Do not take Vardenafil 5 mg with nitrates or certain medications.
• Store Vardenafil 5 mg in a cool, dry place away from children.
• Consult your doctor before starting Vardenafil 5 mg.
• Report any persistent or severe side effects to your doctor.

tucatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Vardenafil 5 mg is a PDE5 inhibitor for erectile dysfunction.
• It helps men achieve and maintain an erection suitable for intercourse.
• Vardenafil 5 mg is often prescribed when other treatments fail.
• This medication can be taken with or without food.
• The effects of Vardenafil 5 mg last about 4-6 hours.
• It is important to follow your healthcare provider’s instructions.
• Avoid high-fat meals close to taking Vardenafil for faster effect.
• Combining Vardenafil 5 mg with recreational drugs is dangerous.
• It may interact with blood pressure medications.
• Do not exceed the prescribed dose to prevent risks.
• Vardenafil 5 mg is generally well-tolerated.
• Always check for contraindications before use.

Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.

Vardenafil dosing information

buprenorphine and vardenafil both increase QTc interval. buprenorphine buccalbuprenorphine buccal and vardenafil both increase QTc interval. buprenorphine buccal and vardenafil both increase QTc interval. buprenorphine subdermal implantbuprenorphine subdermal implant and vardenafil both increase QTc interval. buprenorphine subdermal implant and vardenafil both increase QTc interval.

How does vardenafil work (mechanism of action)?

buprenorphine transdermalbuprenorphine transdermal and vardenafil both increase QTc interval. buprenorphine transdermal and vardenafil both increase QTc interval. buprenorphine, long-acting injectionbuprenorphine, long-acting injection and vardenafil both increase QTc interval. buprenorphine, long-acting injection and vardenafil both increase QTc interval. carbamazepinecarbamazepine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. vardenafil increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended. vilanterol/fluticasone furoate inhaledvardenafil increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. vardenafil increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid coadministration of ziftomenib with other drugs known to prolong the QTc interval. If unavoidable, obtain ECGs when initiating, during concomitant use, and as clinically indicated.

Dosing & Uses

phenoxybenzaminevardenafil increases effects of phenoxybenzamine by pharmacodynamic synergism. vardenafil increases effects of phenoxybenzamine by pharmacodynamic synergism. phentolaminevardenafil increases effects of phentolamine by pharmacodynamic synergism. vardenafil increases effects of phentolamine by pharmacodynamic synergism. prazosinvardenafil increases effects of prazosin by pharmacodynamic synergism. Interrupt ziftomenib with QTc interval > 500 ms or a change from baseline is > 60 ms vardenafil and ziftomenib both increase QTc interval. Interrupt ziftomenib with QTc interval > 500 ms or a change from baseline is > 60 ms zotepinevardenafil increases effects of zotepine by pharmacodynamic synergism. vardenafil increases effects of zotepine by pharmacodynamic synergism. adagrasibadagrasib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

What should I avoid while using vardenafil?

macimorelin and vardenafil both increase QTc interval. mefloquinemefloquine increases toxicity of vardenafil by QTc interval. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents. mefloquine increases toxicity of vardenafil by QTc interval. vardenafil and milsaperidone both increase QTc interval.

What else should I know about vardenafil?

moxisylytevardenafil increases effects of moxisylyte by pharmacodynamic synergism. vardenafil increases effects of moxisylyte by pharmacodynamic synergism. ondansetronondansetron and vardenafil both increase QTc interval. ondansetron and vardenafil both increase QTc interval. oxaliplatin and vardenafil both increase QTc interval. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors adagrasib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors alfuzosinvardenafil and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and vardenafil both increase QTc interval. vardenafil and alfuzosin both increase QTc interval. Monitor blood pressure response to phosphodiesterase type 5 (PDE5) inhibitors in patients receiving concurrent blood pressure lowering therapy. amiodaroneamiodarone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors amiodarone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors apomorphineapomorphine and vardenafil both increase QTc interval. apomorphine and vardenafil both increase QTc interval. aprepitantaprepitant will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors aprepitant will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Proper Use

Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval. givinostatvardenafil and givinostat both increase QTc interval. If unable to avoid coadministration, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Withhold if QTc interval >500 ms or a change from baseline >60 ms. vardenafil and givinostat both increase QTc interval.

Pregnancy and breastfeeding

hydroxychloroquine sulfate and vardenafil both increase QTc interval. idelalisibidelalisib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates idelalisib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates iloperidonevardenafil and iloperidone both increase QTc interval. isoflurane and vardenafil both increase QTc interval.